Triton signed an agreement to acquire a majority stake in Atnahs
Frankfurt (Germany), Basildon (United Kingdom), June 27, 2019 – Funds advised by Triton have signed an agreement to acquire a majority stake of Atnahs, a specialty pharmaceutical business, focussed on the acquisition, development and marketing of mature branded medicines. Terms and conditions of the transaction are not disclosed.
Atnahs is a specialty pharmaceutical business, focused on acquiring mature branded medicines out of large cap and specialty pharma companies and developing its own niche medicines. Atnahs operates a portfolio of over 800 SKUs across more than 130 markets.
Since its establishment in 1997, Triton has sponsored nine funds, focusing on businesses in the industrial, business services, consumer and health sectors.
The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe.Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth.The 38 companies currently in Triton's portfolio have combined sales of around €14.9 billion and around 73,000 employees.
For further information: www.triton-partners.com